Kpti stock forecast a breakout could attract momentum

A breakout could attract momentum traders, particularly if institutional buying picks up following favorable Phase 2 trial data. Focused on retinal diseases, Clearside Biomedical (NASDAQ: CLSD ) may be one of the biotech penny stocks. However, it’s made significant progress that deserves careful consideration. In particular, the company features the first and only Food and Drug Administration-approved therapeutic that’s delivered into the suprachoroidal space ( SCS ). This describes the potential space between the sclera and choroid that traverses the circumference of the posterior segment of the eye. That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism. Market data in the KPTI stock forecast points to RSI levels near 55, suggesting neutral momentum with potential for an upward swing if upcoming trial results beat expectations.